Pipeline
Antibiotic resistance
is a global threat
Classical new antibiotics lose their effectiveness within 5-7 years because bacteria adapt to them very quickly
So, healthcare needs new – "investment-attractive" antibiotics
- •To which resistance DOES NOT form over the time
- •Or resistance might be formed, but NOT faster than 20 years - i.e. while the drug-patent is in effect
- •Effective against infections that would cause those 10 million deaths per year
- •With broad spectrum of antimicrobial activity
Antimicrobial peptides are the base for the development of new drugs and they solve all the problems of "classic" antibiotics:
- •Produced by living cells (including human) to fight cancer and infections
- •More that 3000 natural peptides discovered
- •High activity
- •Low immunogenicity
- •Good biocompatibility
Antimicrobial peptides "cut" bacteria, which leads to their death in 20 min after exposition…
The arrows indicate where the peptide cuts the bacterial cell. Some peptides can do the same with cancer cells. This mechanism of action determines why resistance is not formed to antimicrobial peptides (or is formed, but very slowly).
But…
antimicrobial/anticancer peptides of natural origin might have some disadvantages
PeptiGen Platform
We have developed and tested method for the de novo"design" of new peptides using artificial intelligence (AI) and bioinformatic tools
Our «PeptiGen» platform generates new peptides that have
- •Broad spectrum of antimicrobial action
- •Low toxicity and immunogenicity
- •Effective against infections that will cause 10 million deaths a year
- •Pronounced effect at low doses in animal infection model
PeptiGen
drug development platform
Proof-of-concept
on the example of new peptide antibiotics
Efficacy of some the our AI-generated peptides in experimental carbapenem-resistant K. pneumoniae sepsis
After a single injection of only 100 microgram (!) lethality is reduced by:
- •50% for PEP-137
- •70% for PEP-36
Novel Antimicrobial Peptides Designed Using a Recurrent Neural Network Reduce Mortality in Experimental Sepsis
Bolatchiev Albert
2022. Antibiotics 11, no. 3: 411
Our product
novel peptide-based antibiotics + technology for the development of new patentable peptide compounds
Antibiotics market
Key market drivers
- •Rising number of infectious diseases
- •Global population growth
- •Increasing proportion of infections resistant to antibiotics
- •Loss of "classic" antibiotics
- •Largest market size – Asia
- •Today, every year, 1.2 million people die because they have an antibiotic-resistant infection. By the middle of the 21st century, this figure will reach 10 million annual deaths. We must save these lives
- •Why we should invest in antibiotics — REPAIR Fund
Technologies and Global Markets
2021, BCC Reports
We are looking for investments
So, we have the proof-of-concept –
our platform can generate novel peptides with pharmacological activity and highly effective in animal models
Intellectual property
Lead optimization
Pre-clinical studies
PEP-36DER, PEP-137DER
these are modified derivatives of the peptides PEP-36 and PEP-137, which reduced mortality by 70% and 50%, respectively, in septic mice. These compounds have a pronounced activity against carbapenem-resistant strains of gram-negative bacteria.
PEP-38DER
this is a modified PEP-38, with a pronounced antibacterial activity against carbapenem-resistant strains of Klebsiella and Pseudomonas aeruginosa.
AVP-81 и AVP-84
compounds with potential for the treatment of viral infections caused by SARS-Cov-2 and/or other coronaviruses. In vitro studies are currently being carried out.
ACP/AVP-16DER
was originally de novo developed as an antiviral compound, but it had a potentially significant antitumor effect. In vitro studies are currently being carried out.